Antibody-induced failure of botulinum toxin type B therapy in de novo patients

European Neurology

Volumn 52, Issue 3, 2004, Pages 132-135

  Dressler, Dirk ^a   Bigalke, Hans ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antibodies; Botulinum toxin type A; Botulinum toxin type B; Secondary therapy failure

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN TYPE B ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CASE REPORT; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DYSTONIA; FEMALE; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; XEROSTOMIA;

ADULT; ANTIBODY FORMATION; BOTULINUM TOXINS; FEMALE; HUMANS; MALE; MIDDLE AGED; TORTICOLLIS; TREATMENT FAILURE;

EID: 9244247668     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081463     Document Type: Article

References (21)

1. Tsui JK, Eisen A, Mak E, Carruthers J, Scott A, Calne DB: A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985;12:31431-31436.
2. Jankovic J, Schwartz KS: Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991;48:1253-1256.
3. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD: Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 1992;85:524-529.
4. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P: Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology 1993;43:1715-1718.
5. Greene PE, Fahn S: Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov Disord 1996;11:181-184.
6. Jankovic J, Schwartz K: Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
7. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ,Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-1446.
8. Dressler D, Benecke R, Bigalke H: Botulinum toxin type B (NeuroBloc®) in patients with botulinum toxin type A antibody-induced therapy failure. J Neurol 2003;250:967-969.
9. Consky ES, Basinski A, Belle L, Ranawaya R, Lang AE: The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): Assessment of validity and inter-rater reliability. Neurology 1990;40(suppl 1):445.
10. Dressler D, Rothwell JC Bigalke H: The sternocleidomastoid test: An in-vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 2000;247:630-632.
11. Dressler D, Lange M, Bigalke H: Detecting neutralising antibodies against botulinum toxin type B with a mouse diaphragm assay. 128th Ann Meet Am Neurol Assoc, 2003, p 67.
12. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H: Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies - therapeutic consequences. Exp Neurol 1997;147:96-102.
13. Dressler D: Botulinum toxin therapy failure: Causes, evaluation procedures and management strategies. Eur J Neurol 1997;4(suppl 2):S67-S70.
14. Dressler D: Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 2002;48:26-29.
15. Dressler D: Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 2000;247:809-810.
16. Dressler D: New formulation of Botox®: Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004;251:360.
17. Dressler D, Dirnberger G: Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord 2000;15(suppl 2):51.
18. Setler P: The biochemistry of botulinum toxin type B. Neurology 2000;55(suppl 5):S22-S28.
19. Dressler D, Muenchau A, Bhatia KP, Quinn NP, Bigalke H: Antibody-induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses? Eur Neurol 2002;47:118-121.
20. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.
21. Dressler D, Benecke R: Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-38.